REVOLUTION MEDICINES INC

Insider sell by Revolution Medicines’ General Counsel hints at strategic realignment—evaluate the impact on daraxonrasib and investor confidence.

Insider selling at Revolution Medicines stays routine—key executives trade shares while the stock’s fundamentals and pipeline remain strong.

Insight into Kelsey Stephen Michael’s 10‑b‑5‑1 insider trades at Revolution Medicines: a 32% stake reduction, premium sales, and implications for investors.

Patel Sushil’s 10b5‑1 plan shows 12,000+ shares traded, blending a $37.54 buy with $183–$193 sales—insider strategy signals for Revolution Medicines investors.

Insider buy by CFO Anders Jack signals confidence in REVOLUTION Medicines’ oncology growth—learn why this 10b5‑1 trade matters for investors.

Explore Mancini Anthony’s 10(b)(5)(1) trades at Revolution Medicines—buying and selling large blocks to gauge insider confidence and market timing.

Insider Mark Goldsmith’s bulk buys at under $5 per share signal confidence in Revolution Medicines’ oncology pipeline and $500 M raise, hinting at upside but urging cautious investment pending clinical milestones.

Insider sales by Revolution Medicines’ general counsel reveal routine 10(b)(5) trading, not a warning sign – investors can keep an eye on modest share‑rebalancing amid a still‑strong pipeline.

Insightful look at Margaret Horn’s March 2026 share sale, its tax‑withholding context, and how it reflects insider confidence in Revolution Medicines’ RAS pipeline.

Revolution Medicines insider sales are tax‑driven, not bearish, and fit historic patterns; focus on upcoming RAS(ON) trial data for real catalysts.